402P First-line ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without visceral crisis from the phase II RIGHT choice study

H.A Azim,N.S El Saghir,Y.S Yap,Y Eralp,S-A Im,M.S Sandhu,H Abdel-Razeq,S Gupta,E Artamonova,J Rihani,T Delgar Alfaro,J Wu,H Hu,M Gao,Y-S Lu

doi:10.1016/j.annonc.2023.09.579

402P First-line ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without visceral crisis from the phase II RIGHT choice study

H.A Azim, N.S El Saghir + Show 13 more

https://doi.org/10.1016/j.annonc.2023.09.579

Copy DOI

Journal: Annals of Oncology	Publication Date: Oct 1, 2023
Citations: 2

Affiliation: Cairo University, American University of Beirut Medical Center, Acıbadem Adana Hospital, Seoul National University, Hospital Kuala Lumpur, University of Jordan, Tata Memorial Hospital, Ministry of Health of the Russian Federation, National Taiwan University Hospital

#Visceral Crisis #Ribociclib + Show 7 more

Abstract
Full-Text PDF
Similar Papers

Abstract

402P First-line ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without visceral crisis from the phase II RIGHT choice study

Full Text